Key result
Rivaroxaban use for venous thromboembolism in pediatric patients with hematologic malignancies was characterized using real-world data.
Why the study?
Children with cancer have an increased risk of developing venous thromboembolism, with prevalence varying among pediatric oncology patients.
Key points are not available for this paper at this time.
Offers initial real-world insights into rivaroxaban use; leaves open safety and efficacy questions for prospective trials.
Children with cancer have an increased risk of developing venous thromboembolism (VTE). The prevalence of VTE among pediatric oncology patients is approximately 8% [1], but this estimate varies acc...
No takes yet. Share an insight, caveat, or question.
Sultan et al. (2024) studied this question. Rivaroxaban use for venous thromboembolism in pediatric patients with hematologic malignancies was characterized using real-world data.
Synapse has enriched 5 related papers. Consider them for comparative context: